News: stock, crypto, macro, education

Abbott Reports Impressive First-Quarter 2024 Results and Increases Full-Year Guidance

Abbott Reports Impressive First-Quarter 2024 Results and Increases Full-Year Guidance

Abbott, a global healthcare company, has announced its financial results for the first quarter of 2024, which ended on March 31, 2024. The company reported significant achievements including a total sales revenue of $10.0 billion, marking a 2.2 percent increase. This includes the impact from an expected decline in COVID-19 testing-related sales compared to the previous year.

Significant Growth in Key Areas

The company enjoyed a 10.8 percent organic sales growth in its underlying base business, celebrating the fifth consecutive quarter of double-digit growth. This growth is primarily driven by robust performance in the Medical Devices and Established Pharmaceuticals sectors.

Detailed Financial Metrics

  • GAAP diluted earnings per share (EPS) stood at $0.70, with an adjusted EPS of $0.98 after excluding specified items.
  • Abbott has refined its full-year EPS guidance for 2024, now expecting GAAP diluted EPS to range between $3.25 and $3.40, and adjusted diluted EPS between $4.55 and $4.70.
  • Organic sales growth guidance for 2024, excluding COVID-19 testing-related sales, has been narrowed to between 8.5% and 10.0%.

Innovations and Regulatory Approvals

Innovation remains a key driver for Abbott, with several significant developments:

  • In January, the launch of the Protality™ brand, a new high-protein nutrition shake.
  • In February, the Insulet's Omnipod® 5 Automated Insulin Delivery System received CE Mark approval.
  • In March, completion of enrollment for the Volt CE Mark clinical study focused on treating atrial fibrillation.
  • Recent U.S. FDA approvals in April for TriClip™, a treatment for tricuspid regurgitation, and the i-STAT® TBI test for assessing traumatic brain injuries.

Sales Overview by Segment

  • Nutrition: Sales totaled $2.068 billion with an 8.1% growth in the U.S. and 3.0% internationally.
  • Diagnostics: Reported sales were $2.214 billion, although impacted by a decrease in COVID-19 testing-related sales.
  • Medical Devices: Achieved $4.453 billion in sales, marked by a 14.2% increase largely due to strong sales in Diabetes Care and Structural Heart devices.
  • Established Pharmaceuticals: Sales in key emerging markets rose to $1.226 billion, showing a 13.7% organic growth driven by sectors like respiratory and women's health.

More articles